Comparative risk of the neurodegenerative outcomes between sodium-glucose co-transporter 2 (SGLT2) inhibitors and thiazolidinediones in type 2 diabetes: a multicentre cohort study using the Korean hea
5 hours ago
- #cognitive decline
- #neurodegenerative diseases
- #diabetes
- Type 2 diabetes mellitus increases the risk of cognitive decline and dementia by 1.5-2 times.
- The study compares the neuroprotective effects of SGLT2 inhibitors and thiazolidinediones (TZDs) in preventing neurodegenerative outcomes like stroke, dementia, and Alzheimer's disease (AD).
- A multicentre, retrospective, observational cohort study was conducted using data from 11 South Korean healthcare institutions (2014-2025).
- Participants were aged 40+ and newly prescribed either SGLT2 inhibitors or TZDs, with propensity score matching (1:1) based on sex.
- Results showed SGLT2 inhibitors had no significant difference in stroke risk but significantly reduced dementia (HR 0.66) and AD (HR 0.54) risks compared to TZDs.
- The protective effects of SGLT2 inhibitors on dementia and AD were consistent across multiple hospital sites.
- SGLT2 inhibitors may offer selective neuroprotective benefits for diabetic patients at risk of cognitive decline.